Literature DB >> 24608188

Venous thromboembolism and cancer risk among elderly adults in the United States.

Morgan A Marks1, Eric A Engels.   

Abstract

BACKGROUND: Few studies have evaluated cancer risk following venous thromboembolism (VTE). Both VTE and cancer disproportionately affect older adults.
METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we evaluated 1.2 million cancer cases and 200,000 controls (66-99 years old, 1992-2005). VTEs occurring before selection were identified using Medicare claims. Logistic regression was used to estimate ORs.
RESULTS: VTE was present in 2.5% of cases and 2.2% of controls. VTE was associated with risk of cancers of the lung [OR = 1.18; 95% confidence interval (CI), 1.12-1.23], stomach (OR = 1.19; 95% CI, 1.09-1.30), small intestine (OR = 1.42; 95% CI, 1.17-1.71), colon (OR = 1.25; 95% CI, 1.18-1.31), gallbladder (OR = 1.39; 95% CI, 1.16-1.67), pancreas (OR = 1.53; 95% CI, 1.43-1.64), soft tissue (OR = 1.43; 95% CI, 1.21-1.68), ovary (OR = 1.35; 95% CI, 1.22-1.50), and kidney/renal pelvis (OR = 1.34; 95% CI, 1.23-1.46), and melanoma (OR = 1.17; 95% CI, 1.08-1.27), non-Hodgkin lymphoma (OR = 1.27; 95% CI, 1.20- 1.35), myeloma (OR = 1.48; 95% CI, 1.35-1.63), and acute myeloid leukemia (OR = 1.35; 95% CI, 1.19-1.54). Strongest risks were observed within 1 year of VTE diagnosis, but risks were elevated more than 6 years after VTE for colon cancer (OR = 1.24; 95% CI, 1.12-1.37), pancreatic cancer (OR = 1.33; 95% CI, 1.15-1.54), and myeloma (OR = 1.35; 95% CI, 1.10-1.66). Few differences in risk were observed by VTE subtype. Cancers of the lung, stomach, and pancreas were more likely to have distant metastases within one year after VTE.
CONCLUSION: Among elderly adults, cancer risk is elevated following VTE diagnosis. IMPACT: Short-term associations with cancer are likely driven by enhanced screening following VTE and reverse causation. While obesity, other comorbidities, and smoking cannot be excluded as explanations, longer-term elevations for select cancers suggest that some VTEs may be caused by cancer precursors. ©2014 AACR.

Entities:  

Mesh:

Year:  2014        PMID: 24608188      PMCID: PMC4020513          DOI: 10.1158/1055-9965.EPI-13-1138

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  47 in total

1.  Incidence of venous thromboembolism in patients hospitalized with cancer.

Authors:  Paul D Stein; Afzal Beemath; Frederick A Meyers; Elias Skaf; Julia Sanchez; Ronald E Olson
Journal:  Am J Med       Date:  2006-01       Impact factor: 4.965

2.  Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults.

Authors:  Richard H White; Helen K Chew; Hong Zhou; Arti Parikh-Patel; David Harris; Danielle Harvey; Theodore Wun
Journal:  Arch Intern Med       Date:  2005 Aug 8-22

3.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

Authors:  N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

4.  Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort.

Authors:  Alpa V Patel; Carmen Rodriguez; Leslie Bernstein; Ann Chao; Michael J Thun; Eugenia E Calle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

5.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

Authors:  Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

6.  Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.

Authors:  Johannes J A Auwerda; Pieter Sonneveld; Monica P M de Maat; Frank W G Leebeek
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

7.  Malignancies, prothrombotic mutations, and the risk of venous thrombosis.

Authors:  Jeanet W Blom; Carine J M Doggen; Susanne Osanto; Frits R Rosendaal
Journal:  JAMA       Date:  2005-02-09       Impact factor: 56.272

8.  Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

Authors:  Alok A Khorana; Charles W Francis; Eva Culakova; Nicole M Kuderer; Gary H Lyman
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

Review 9.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

10.  Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study.

Authors:  J W Blom; J P M Vanderschoot; M J Oostindiër; S Osanto; F J M van der Meer; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824

View more
  8 in total

1.  Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Garth W Tormoen; Todd H Wagner; Parag Mallick; Owen J T McCarty
Journal:  Converg Sci Phys Oncol       Date:  2017-05-17

2.  Patient Adherence and Experience with Extended Use of Prophylactic Low-Molecular-Weight Heparin Following Pancreas and Liver Resection.

Authors:  Madeline Lemke; Kaitlyn Beyfuss; Julie Hallet; Natalie G Coburn; Calvin H L Law; Paul J Karanicolas
Journal:  J Gastrointest Surg       Date:  2016-09-29       Impact factor: 3.452

3.  Occult cancer in patients with deep-vein thrombosis in a general hospital at Mexico City: A pilot study.

Authors:  Christian O Ramírez-Serrano Torres; Edgardo Román-Guzmán; Carlos-Manuel Ortiz-Mendoza
Journal:  J Res Med Sci       Date:  2017-05-30       Impact factor: 1.852

Review 4.  Screening for Occult Cancer in Patients with Venous Thromboembolism.

Authors:  Julien D'Astous; Marc Carrier
Journal:  J Clin Med       Date:  2020-07-27       Impact factor: 4.241

5.  Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.

Authors:  Tamara A Sussman; Hong Li; Brian Hobbs; Pauline Funchain; Keith R McCrae; Alok A Khorana
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 12.469

6.  Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society.

Authors:  Frederikus A Klok; Walter Ageno; Cihan Ay; Magnus Bäck; Stefano Barco; Laurent Bertoletti; Cecilia Becattini; Jørn Carlsen; Marion Delcroix; Nick van Es; Menno V Huisman; Luis Jara-Palomares; Stavros Konstantinides; Irene Lang; Guy Meyer; Fionnuala Ní Áinle; Stephan Rosenkranz; Piotr Pruszczyk
Journal:  Eur Heart J       Date:  2022-01-25       Impact factor: 29.983

7.  Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study.

Authors:  Jong-Chan Lee; Young Sun Ro; Junhyeon Cho; Yohan Park; Ji Hye Lee; Jin-Hyeok Hwang; Hye Jin Choi; Soohyeon Lee
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 8.  Occult cancer detection in venous thromboembolism: the past, the present, and the future.

Authors:  Faizan Khan; Alvi Rahman; Marc Carrier
Journal:  Res Pract Thromb Haemost       Date:  2017-06-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.